These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 11314743)

  • 21. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.
    Owecki M; Sowiński J
    Pharm World Sci; 2006 Apr; 28(2):73-5. PubMed ID: 16791713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy.
    Hiromatsu Y; Tanaka K; Sato M; Kuroki T; Nonaka K; Kojima K; Nishimura H; Nishida H; Kaise N
    Endocr J; 1993 Feb; 40(1):63-72. PubMed ID: 7951498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
    Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
    Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum levels of soluble TNFalpha receptors (sTNFR1 and sTNFR2) during corticosteroid treatment in patients with Graves' ophthalmopathy.
    Myśliwiec J; Kretowski A; Stepień A; Kinalska I
    Immunol Invest; 2004 Feb; 33(1):61-8. PubMed ID: 15015833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
    Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
    Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy.
    Matejka G; Vergès B; Vaillant G; Petit JM; Brun-Pacaud A; Rudoni S; Brun JM
    Horm Metab Res; 1998 Feb; 30(2):93-8. PubMed ID: 9543692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
    Konuk O; Atasever T; Unal M; Ayvaz G; Yetkin I; Cakir N; Arslan M; Hasanreisoglu B
    Thyroid; 2002 Jul; 12(7):603-8. PubMed ID: 12193305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The combined therapy of Basedow's ophthalmopathy with retrobulbar radiotherapy and i.v. immunoglobulins. The preliminary results].
    Antonelli A; Saracino A; Alberti B; Melosi A; Cartei F; Lepri A; Laddaga M; Baschieri L
    Clin Ter; 1992 Jan; 140(1):25-31. PubMed ID: 1526094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M; Hunder GG; Easley KA; Calamia KT; Matteson EL; Griffing WL; Younge BR; Weyand CM; Goronzy JJ
    Arthritis Rheum; 2006 Oct; 54(10):3310-8. PubMed ID: 17009270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum L-selectin and ICAM-1 in patients with Graves' ophthalmopathy during treatment with corticosteroids.
    Myśliwiec J; Kretowski A; Szelachowska M; Topolska J; Mikita A; Kinalska I
    Immunol Lett; 2001 Oct; 78(3):123-6. PubMed ID: 11578685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome.
    Hart RH; Kendall-Taylor P; Crombie A; Perros P
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):328-36. PubMed ID: 16117697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic role of adhesion molecules sELAM-1 and sICAM-1 in glucocorticoid therapy of active ophthalmopathy].
    Modelska-Ziółkiewicz A; Gembicki M; Bednarek J; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):469-75. PubMed ID: 14768175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orbital cobalt radiotherapy and systemic or retrobulbar corticosteroids for Graves' ophthalmopathy.
    Pinchera A; Marcocci C; Bartalena L; Panicucci M; Marconcini C; Lepri A; Cavallacci G; Cartei F; Laddaga M
    Horm Res; 1987; 26(1-4):177-83. PubMed ID: 3596466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Success Treatment of Severe and Active Graves' Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone.
    Pramono LA
    Acta Med Indones; 2023 Oct; 55(4):475-477. PubMed ID: 38213047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.
    Kendall-Taylor P; Crombie AL; Stephenson AM; Hardwick M; Hall K
    BMJ; 1988 Dec; 297(6663):1574-8. PubMed ID: 2906260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucocorticoids in the medical management of Graves' ophthalmopathy.
    Hart RH; Perros P
    Minerva Endocrinol; 2003 Sep; 28(3):223-31. PubMed ID: 14605604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic responses to corticosteroids in Graves' ophthalmopathy.
    Chang TC; Kao SC; Hsiao YL; Lu CP; Huang KM; Tzeng SS
    J Formos Med Assoc; 1996 Nov; 95(11):833-8. PubMed ID: 8990770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The effects of intensive DMPA regimen in the treatment of Graves' ophthalmopathy].
    Wei S; Tong N; Luo Q; Tian H; Yu Y; Liu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1996 Sep; 27(3):306-9. PubMed ID: 9389069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The influence of corticosteroids on IL-6/IL-6R system in patients with Graves' ophthalmopathy].
    Myśliwiec J; Kretowski A; Topolska J; Stepień A; Kinalska I
    Pol Arch Med Wewn; 2002 Aug; 108(2):739-44. PubMed ID: 12476893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.